查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012300

HIV疫苗市場：按疫苗類型、給藥途徑、標靶抗原和最終用戶分類的全球市場預測 – 2026–2032年

HIV Vaccines Market by Vaccine Type, Route Of Administration, Target Antigen, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年 HIV 疫苗市場價值為 4.3852 億美元，預計到 2025 年將成長至 4.9438 億美元，複合年成長率為 13.27%，到 2032 年將達到 11.8844 億美元。

主要市場統計數據
基準年 2024 4.3852億美元
預計年份：2025年 4.9438億美元
預測年份 2032 1,188,440,000 美元
複合年成長率 (%) 13.27%

簡要概述正在重塑 HIV 疫苗研發和計畫重點的協同科學、監管和營運趨勢。

愛滋病疫苗的研發在免疫學、病毒學和全球公共衛生策略的交叉領域中發揮著至關重要的作用。抗原設計、遞送平台和免疫調節技術的最新科學進展重新定義了技術上可實現的範圍，而監管環境和臨床試驗設計也在不斷調整以適應新的方法。相關人員公共衛生機構、學術聯盟和私人研發機構在內的各利益相關方，都在努力應對由複雜的科學權衡、不斷變化的社會期望以及對永續生產和分銷方式的需求所構成的挑戰。

平台多樣化、給藥途徑最佳化、監管協調和合作模式如何共同改變愛滋病疫苗策略。

在愛滋病疫苗領域，正在發生多項變革性變化，這些變化正在重新定義研究策略、投資重點和合作框架。首先，平台多樣化正在推動並行研發路徑的形成。雖然重組蛋白和類病毒顆粒（VLPs）等傳統方法在某些免疫譜中仍發揮重要作用，但基於核苷酸的平台，例如常規mRNA和自擴增mRNA，由於其設計週期短、抗原呈現能力靈活，正吸引越來越多的關注。同時，病毒載體和胜肽策略也在不斷改進，以提高安全性、增強免疫反應的持久性以及靶向細胞介導免疫。

本研究評估了 2025 年關稅變化將如何重塑整個 HIV 疫苗價值鏈的採購、製造地和合作生產策略。

預計在2025年前後，關稅政策的變化將對疫苗供應鏈、籌資策略和跨境合作帶來新的挑戰。某些原料、組件和成品關稅的提高可能會影響製造地的成本競爭力，並影響成品疫苗和關鍵中間體的生產地點選擇。這些變化使得供應鏈透明度和策略採購（減少對單一國家供應商關鍵試劑和耗材的依賴）變得更加重要。

將疫苗類型、平台技術、給藥途徑、終端用戶趨勢和分銷方式與策略決策聯繫起來的綜合細分洞察。

詳細的細分分析揭示了產品策略、技術選擇、給藥途徑、用戶需求和通路如何相互作用，從而決定研發和商業化的優先順序。在評估疫苗類型時，預防性疫苗包括傳統的去活化病毒疫苗、減毒活病毒疫苗、重組蛋白製劑和類病毒顆粒（VLP）候選疫苗，每種疫苗都有不同的免疫抗原性特徵和生產挑戰。另一方面，治療性候選疫苗針對不同的終點和患者群體，這會影響臨床試驗設計以及與醫療保健系統的長期合作。技術選擇涵蓋DNA、mRNA、胜肽和病毒載體平台，其中mRNA本身可進一步區分為傳統的mRNA構建體和旨在提高抗原表達和給藥效率的自擴增mRNA。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和戰略挑戰將決定監管協調和實施準備。

區域趨勢對愛滋病疫苗的研發、監管策略和部署策略規劃至關重要。在美洲，各監管轄區擁有先進的臨床試驗基礎設施和多元化的支付方環境，這有利於分階段進行臨床試驗，並促進與學術機構和商業生產商的夥伴關係。由於各國的智慧財產權框架和採購機制各不相同，跨境策略通常優先考慮儘早與各國監管機構和支付方接洽，以建構符合報銷預期的證據材料。

領先的研究機構、開發公司和製造合作夥伴如何建立其產品組合、合作關係和製造方法，以獲得轉化優勢？

構成愛滋病疫苗生態系統的關鍵機構正在根據科學進步和不斷變化的營運限制調整其產品組合和合作方式。公共研究機構持續提供基礎免疫學見解以支持轉化項目，而製藥和生物技術開發公司則透過將新型抗原設計與先進的遞送平台相結合，最佳化免疫反應的持久性和廣度。戰略合作夥伴關係通常將平台專家與提供臨床試驗基礎設施和區域生產能力的機構相結合，從而實現更快的規模化生產和更有效率的受試者招募。

專案領導者需要採取切實可行的策略行動，以平衡平台選擇、供應鏈韌性、監管參與和公平准入夥伴關係。

產業領導者應將短期戰術性行動與策略藍圖相協調，以平衡科學風險、營運韌性和市場准入目標。在早期產品組合中，應優先考慮平台獨立性，以確保在重組蛋白、類病毒顆粒、核苷酸構建體和病毒載體之間保持選擇性。這種方法允許根據臨床數據揭示的保護性相關性和持久性訊號調整項目。同時，應投資特定療法的下游能力，例如製劑科學、低溫運輸物流和給藥途徑最佳化，以減少後期轉化研究的阻力。

透過將對專家的直接訪談與二手科學和監管證據相結合，我們透過高度透明和可重複的調查方法，為可操作的方案提供見解。

本報告整合了一手和二手資料，建構了一個嚴謹且可重複的愛滋病疫苗研發現狀圖景。一手資料包括對臨床研究人員、生產專家、監管顧問和採購相關人員的結構化訪談，以及來自積極應對研發和規模化挑戰的後期專案經理的匿名定性回饋。二手資料則利用同儕審查文獻、已發布的監管指南、臨床試驗註冊數據和會議報告，對科學趨勢進行多角度檢驗，並為轉化醫學假設提供支持。

綜合考慮技術、監管、供應鏈和區域因素，制定將愛滋病毒疫苗創新轉化為可用解決方案的切實可行的途徑。

總之，當前愛滋病疫苗的發展現狀呈現出技術多樣化加速、監管預期不斷變化以及對供應鏈和區域部署實際情況日益關注的特徵。那些保持平台柔軟性、投資於與其所選給藥途徑相匹配的運營能力並積極與當地相關人員合作的研發者，將更有利於把科學進步轉化為適銷產品。關稅和貿易政策的變化凸顯了製定具有韌性的採購和生產策略的重要性，而市場碎片化和區域趨勢則強調了採取能夠反映最終用戶需求和分銷管道實際情況的個人化方法的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：愛滋病疫苗市場：依疫苗類型分類

  • 為了預防
    • 胜肽疫苗
    • 減毒活病毒疫苗
    • DNA疫苗
    • 藥效疫苗
  • 治療

第9章：愛滋病疫苗市場：依給藥途徑分類

  • 肌肉內部
  • 鼻內
  • 皮下

第10章：愛滋病疫苗市場：以標靶抗原分類

  • 包膜糖蛋白（Env）
  • 內部 Gag 蛋白
  • Pol蛋白

第11章：愛滋病疫苗市場：依最終用戶分類

  • 診所
  • 醫院
  • 研究機構
  • 公共衛生機構與政府

第12章 愛滋病疫苗市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：愛滋病疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 愛滋病疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國：愛滋病疫苗市場

第16章 中國：愛滋病疫苗市場

第17章 競爭格局

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • AlphaVax, Inc.
  • BioNTech SE
  • GeoVax Labs, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • ImmunityBio, Inc.
  • Johnson & Johnson Services, Inc.
  • Moderna, Inc.
  • Pfizer Inc.
  • Vir Biotechnology, Inc
Product Code: MRR-4312A385A507

The HIV Vaccines Market was valued at USD 438.52 million in 2024 and is projected to grow to USD 494.38 million in 2025, with a CAGR of 13.27%, reaching USD 1,188.44 million by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 438.52 million
Estimated Year [2025] USD 494.38 million
Forecast Year [2032] USD 1,188.44 million
CAGR (%) 13.27%

Concise orientation to the converging scientific, regulatory, and operational forces reshaping HIV vaccine development and program priorities

HIV vaccine development occupies a pivotal role at the intersection of immunology, virology, and global public health strategy. Recent scientific advances in antigen design, delivery platforms, and immune modulation techniques have reframed what is technically achievable, while regulatory frameworks and clinical trial designs continue to adapt to novel modalities. Stakeholders across public health institutions, academic consortia, and private developers are navigating a landscape shaped by complex scientific trade-offs, evolving public expectations, and the need for sustainable manufacturing and distribution approaches.

This executive summary aims to synthesize the most consequential developments and to surface strategic implications for decision-makers. It clarifies how shifts in platform technology preferences, regulatory alignment, and geopolitical dynamics are influencing priorities across development portfolios. The summary also highlights how route of administration choices, end-user requirements, and distribution channels intersect with technology selection and clinical strategy. By framing these factors together, the introduction sets the stage for actionable insight that supports program prioritization, partnership formation, and operational planning across research, clinical, and commercial stakeholders.

How platform diversification, administration route optimization, regulatory harmonization, and collaborative models are jointly transforming HIV vaccine strategies

The HIV vaccine landscape is undergoing several transformative shifts that are redefining research strategies, investment priorities, and the architecture of collaboration. First, platform diversification is driving parallel development pathways: while traditional approaches like recombinant protein and virus-like particle constructs retain importance for certain immune profiles, nucleotide-based platforms such as conventional mRNA and self-amplifying mRNA are catalyzing renewed interest due to their rapid design cycles and flexible antigen presentation. At the same time, viral vectors and peptide strategies continue to be refined to improve safety, durability of response, and targeted cellular immunity.

Second, integration of immunogen design with delivery route selection is emerging as a critical determinant of clinical strategy. Intramuscular administration remains the default for many candidates, but intranasal and subcutaneous routes are being reexamined for mucosal immunity and dose-sparing advantages respectively. Third, regulatory agencies are increasingly emphasizing harmonized endpoints, adaptive trial designs, and real-world data integration, which accelerates translational pathways but requires robust post-authorization evidence plans. Finally, collaboration models are shifting: multi-stakeholder consortia, public-private partnerships, and novel licensing arrangements are becoming standard mechanisms to balance scientific risk, capital intensity, and global access objectives. These shifts collectively expand the set of feasible strategies for program leaders while raising the premium on integrated technical, regulatory, and commercial planning.

Assessing how 2025 tariff shifts are reshaping sourcing, manufacturing footprints, and collaborative production strategies across the HIV vaccine value chain

Tariff policy changes announced in and around 2025 have introduced a new set of considerations for vaccine supply chains, procurement strategies, and cross-border collaboration. Increased duties on certain raw materials, components, and finished products can impact the cost competitiveness of manufacturing footprints and influence decisions about where to site production for finished vaccines or key intermediates. These dynamics amplify the importance of supply chain visibility and of strategic sourcing that reduces dependence on single-country suppliers for critical reagents and consumables.

Beyond direct cost effects, tariff shifts can create operational frictions that extend lead times and complicate inventory planning. Manufacturers and distributors respond by diversifying supplier networks, increasing onshore or nearshore manufacturing capacity, and renegotiating long-term supply agreements to incorporate tariff contingencies. Procurement teams must also adjust contracting language to address customs compliance, tariff mitigation clauses, and potential regulatory variances that arise when products cross multiple jurisdictions.

Importantly, tariffs can influence collaborative structures: research collaborations and manufacturing partnerships may emphasize in-region production and technology transfer to avoid cross-border cost penalties and to align with national industrial policies. Policymakers and industry alike are assessing how tariff instruments affect equitable access objectives, with a growing emphasis on cooperative mechanisms that preserve affordability while supporting resilient manufacturing ecosystems.

Integrated segmentation insights that connect vaccine type, platform technology, administration route, end-user dynamics, and distribution choices to strategic decision-making

A nuanced view of segmentation reveals how product strategy, technology choice, administration route, user needs, and distribution pathways interact to determine development and commercialization priorities. When evaluating vaccine type, preventive approaches encompass traditional inactivated virus, live attenuated constructs, recombinant protein assets, and virus-like particle candidates, each offering distinct immunogenicity profiles and manufacturing implications; therapeutic candidates pursue different endpoints and patient cohorts, influencing clinical design and long-term engagement with healthcare systems. Technology selection spans DNA, mRNA, peptide, and viral vector platforms, where the mRNA category itself differentiates between conventional mRNA constructs and self-amplifying mRNA that aim to enhance antigen expression and dose efficiency.

Route of administration considerations-intramuscular, intranasal, and subcutaneous-affect both the immunological rationale and the operational logistics of deployment, shaping cold chain requirements and administration training. End-user segmentation highlights divergent requirements from clinics, hospitals, pharmaceutical companies, and research institutes; within clinics, the distinction between hospital-affiliated clinics and standalone clinics informs procurement channels and patient flow design, while private and public hospitals exhibit different purchasing frameworks and budgetary cycles. Distribution channel choices, including direct sales, online sales, and retail pharmacies, further determine engagement models with healthcare providers and patient access pathways. Together, these segmentation dimensions create a multidimensional decision matrix for developers and program managers that must be reconciled across scientific, regulatory, and commercial timelines.

Regional dynamics and strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory alignment and deployment readiness

Regional dynamics are central to strategic planning for HIV vaccine development, regulatory strategy, and deployment. In the Americas, regulatory jurisdictions exhibit a mix of advanced clinical trial infrastructure and diverse payer landscapes, which encourages staged clinical pathways and partnerships with both academic centers and commercial manufacturers. Intellectual property frameworks and procurement mechanisms vary across countries, so cross-border strategies often prioritize early engagement with national regulators and payers to align evidence packages with reimbursement expectations.

Europe, Middle East & Africa presents a complex mosaic where regulatory harmonization initiatives coexist with significant variability in manufacturing capacity and healthcare access. This region emphasizes the need for flexible development plans that accommodate diverse clinical trial populations and that integrate technology transfer elements to build sustainable local capacity. Engagement with regional public health bodies and multilateral procurement entities is often essential to ensure broad access and to coordinate rollout priorities.

Asia-Pacific demonstrates a range of capabilities from high-volume manufacturing hubs to rapidly modernizing regulatory systems and extensive clinical trial networks. Developers frequently pursue regional manufacturing arrangements and strategic licensing to leverage production scale and to navigate national regulatory requirements. Across all regions, local stakeholder relationships, regulatory clarity, and manufacturing resilience remain key determinants of how quickly and effectively vaccine candidates progress from development to delivery.

How leading research institutes, developers, and manufacturing partners are structuring portfolios, collaborations, and manufacturing approaches to gain translational advantage

Leading organizations across the HIV vaccine ecosystem are evolving their portfolios and partnership approaches in response to scientific progress and shifting operational constraints. Public research institutions continue to supply fundamental immunology insights that feed translational programs, while pharmaceutical and biotech developers are combining novel antigen designs with advanced delivery platforms to optimize immune durability and breadth. Strategic collaborations frequently pair platform specialists with organizations that provide clinical trial infrastructure or regional manufacturing capacity, enabling faster scale-up and more efficient study enrollment.

Companies that integrate modular manufacturing capabilities and flexible CMC (chemistry, manufacturing, and controls) processes tend to manage clinical transitions more smoothly. Firms investing in cold chain innovation, quality-by-design manufacturing, and scalable analytics strengthen their ability to support multi-regional rollouts. Meanwhile, contract development and manufacturing organizations (CDMOs) that offer end-to-end services and regulatory experience are increasingly central to program timelines, especially where in-region production or technology transfer is required. Across the ecosystem, competitive advantage accrues to entities that align scientific novelty with operational execution, regulatory foresight, and collaborative agility.

Practical strategic actions for program leaders to balance platform optionality, supply chain resilience, regulatory engagement, and equitable access partnerships

Industry leaders should align near-term tactical actions with a strategic roadmap that balances scientific risk, operational resilience, and access objectives. Prioritize platform agnosticism in early-stage portfolios to preserve optionality between recombinant protein, virus-like particles, nucleotide-based constructs, and viral vectors; this approach allows programs to pivot as clinical data clarifies correlates of protection and durability signals. Simultaneously, invest in modality-specific downstream capabilities such as formulation science, cold chain logistics, and route-of-administration optimization to reduce late-stage translational friction.

Strengthen supply chain resilience by diversifying suppliers for critical inputs, exploring nearshoring or regional manufacturing partnerships, and embedding tariff contingency clauses in procurement contracts. Enhance regulatory strategy by engaging regulators early and pursuing harmonized endpoints and adaptive trial frameworks that support accelerated evidence generation while maintaining robust safety oversight. Finally, develop partnership models that enable technology transfer, local capacity building, and equitable access arrangements; such models should include clear governance, IP management strategies, and shared go-to-market plans that align incentives across public and private stakeholders. These actions collectively reduce program risk and increase the likelihood that promising candidates can progress efficiently from clinical proof-of-concept to broad availability.

Transparent, reproducible research methodology combining primary expert interviews and secondary scientific and regulatory evidence to inform actionable program insights

This report synthesizes primary and secondary inputs to construct a rigorous, reproducible view of the HIV vaccine landscape. Primary inputs include structured interviews with clinical investigators, manufacturing experts, regulatory advisors, and procurement stakeholders, combined with anonymized qualitative feedback from late-stage program managers who are actively navigating development and scale-up challenges. Secondary inputs draw on peer-reviewed literature, public regulatory guidance, clinical trial registries, and conference disclosures to triangulate scientific trends and to validate translational assumptions.

Analysis prioritizes methodological transparency: assumptions about technology performance, supply chain constraints, and regulatory pathways are documented, and sensitivity checks explore alternative scenarios for platform adoption and manufacturing strategies. Where applicable, conclusions emphasize evidence-based linkages rather than speculative projections. The methodology supports custom filtering by technology, route of administration, and region, enabling tailored extractable insights for decision-makers who require focused analysis for partnerships, procurement, or clinical strategy development.

Synthesis of technology, regulatory, supply chain, and regional considerations that define the practical pathways to translating HIV vaccine innovation into accessible solutions

In conclusion, the HIV vaccine landscape is characterized by accelerating technological diversity, evolving regulatory expectations, and heightened attention to supply chain and regional deployment realities. Developers who maintain platform flexibility, invest in operational capabilities that align with chosen administration routes, and proactively engage with regional stakeholders will be better positioned to translate scientific advances into deliverable products. Tariff and trade policy shifts underscore the importance of resilient sourcing and manufacturing strategies, while segmentation and regional dynamics highlight the need for tailored approaches that reflect end-user requirements and distribution channel realities.

The path from promising immunogen to widely accessible vaccine requires integrated planning across science, manufacturing, regulation, and commercial pathways. Strategic partnerships, modular manufacturing approaches, and early regulatory dialogue will continue to accelerate program progression. Ultimately, successful programs will be those that pair technical innovation with pragmatic execution plans that anticipate policy and logistical constraints while centering equitable access objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. HIV Vaccines Market, by Vaccine Type

  • 8.1. Preventive
    • 8.1.1. Peptide Vaccines
    • 8.1.2. Live-attenuated Vaccines
    • 8.1.3. DNA Vaccines
    • 8.1.4. mRNA Vaccines
  • 8.2. Therapeutic

9. HIV Vaccines Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Intranasal
  • 9.3. Subcutaneous

10. HIV Vaccines Market, by Target Antigen

  • 10.1. Envelope Glycoproteins (Env)
  • 10.2. Internal Gag Protein
  • 10.3. Pol Proteins

11. HIV Vaccines Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Research Institutes
  • 11.4. Public Health Agencies & Governments

12. HIV Vaccines Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. HIV Vaccines Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. HIV Vaccines Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States HIV Vaccines Market

16. China HIV Vaccines Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2024
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2024
  • 17.3. Product Portfolio Analysis, 2024
  • 17.4. Benchmarking Analysis, 2024
  • 17.5. AlphaVax, Inc.
  • 17.6. BioNTech SE
  • 17.7. GeoVax Labs, Inc.
  • 17.8. Gilead Sciences, Inc.
  • 17.9. GlaxoSmithKline PLC
  • 17.10. ImmunityBio, Inc.
  • 17.11. Johnson & Johnson Services, Inc.
  • 17.12. Moderna, Inc.
  • 17.13. Pfizer Inc.
  • 17.14. Vir Biotechnology, Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL HIV VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HIV VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HIV VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HIV VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HIV VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HIV VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HIV VACCINES MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HIV VACCINES MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HIV VACCINES MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HIV VACCINES MARKET SIZE, BY ENVELOPE GLYCOPROTEINS (ENV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HIV VACCINES MARKET SIZE, BY ENVELOPE GLYCOPROTEINS (ENV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HIV VACCINES MARKET SIZE, BY ENVELOPE GLYCOPROTEINS (ENV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HIV VACCINES MARKET SIZE, BY INTERNAL GAG PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HIV VACCINES MARKET SIZE, BY INTERNAL GAG PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HIV VACCINES MARKET SIZE, BY INTERNAL GAG PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HIV VACCINES MARKET SIZE, BY POL PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HIV VACCINES MARKET SIZE, BY POL PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HIV VACCINES MARKET SIZE, BY POL PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HEALTH AGENCIES & GOVERNMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HEALTH AGENCIES & GOVERNMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HEALTH AGENCIES & GOVERNMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS HIV VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HIV VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GCC HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 114. GCC HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 116. GCC HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. G7 HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 132. G7 HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 134. G7 HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. NATO HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 138. NATO HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 140. NATO HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES HIV VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA HIV VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)